Market Leadership in Sight as Eli Lilly’s Oral ...

By Rene Pretorius

April 21, 2025

Summary Eli Lilly's oral GLP-1 medication, orforglipron, has completed a Phas...
Environmental Exposures and Pediatric Thyroid Cancer Risk: Key Findings from ...
Capivasertib Cost-Effectiveness in Advanced Breast Cancer
Reserve Antibiotics Benefits: G-BA Designates Meropenem/Vaborbactam as Critic...
Sugary Drinks Cancer Risk: Women Face Higher Oral Cavity Cancer Threat
Cost-Effective HIV PrEP: CAB-LA Transforms Prevention
Neoadjuvant Immunotherapy Efficacy: Enhancing Treatment Strategies for Head a...
Enhancing UK Clinical Trials Inclusivity: Opportunities and Innovations in Me...
Cost-Effective Interventions for HIV, Malaria, Syphilis, and TB in 128 Countries
Challenges in Accelerating Innovative Paediatric Medicine
Balancing Pandemic Preparedness Priorities and Military Spending
Exploring the MASLD CKD Socioeconomic Link
Toripalimab Evidence Journey in Cancer Care